A Study of Degarelix in Patients With Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

409

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Prostate Cancer
Interventions
DRUG

Degarelix

Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.

DRUG

Degarelix

Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).

DRUG

Leuprolide

Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each)

Trial Locations (59)

Unknown

Alabama Clinical Research, Inc, Alexander City

Urology Center of Alabama, PC, Homewood

Advanced Urology Medical Center, Anaheim

Peninsula Urology Medical Center, Atherton

Urology Associates of Central California, Fresno

South Orange County Medical Research Center, Laguna Hills

Atlantic Urology Medical Group, Long Beach

San Bernardino Urological Associates, San Bernardino

San Diego Uro-Research, San Diego

Santa Barbara Clinical Research, Santa Barbara

University of Colorado Health Sciences Center, Aurora

The Urology Center of Colorado, Denver

Urology Associates Research, Englewood

Connecticut Clinical Research Center, Middlebury

Grove Hill Medical Center, New Britain

Walter Reed Army Hospital Medical Center, Washington D.C.

South Florida Medical Research, Aventura

Urology Health Solutions, Inc, Celebration

Florida Urology Physicians, Fort Myers

University of Florida, Gainesville

Winter Park Urology Associates, Orlando

Southeastern Urology Center, PA, Tallahassee

Tampa Bay Urology, Tampa

Advanced Research Institute, Inc, Trinity

Urology Enterprises, Marietta

Midwest Urology/RMD Clinical Research Institute, Melrose Park

Deaconess Clinic Inc, Evansville

Northeast Indiana Research, Fort Wayne

Metropolitan Urology, PSC, Jeffersonville

Regional Urology, Lic, Shreveport

Chesapeake Urology Associates, Baltimore

Chesapeake Urology Research Associates, Baltimore

Chesapeake Urology Research Associates, Glen Burnie

Myron Murdock M.D. LLC, Greenbelt

Chesapeake Urology Associates, PA, Towson

Urology Associates of Englewood, Englewood

Hamilton Urology PA, Hamilton

Lawrenceville Urology, Lawrenceville

Nationsmed Clinical Research, Perth Amboy

Center for Urologic Care, Voorhees Township

Delaware Valley Urology LLC, Woodlane

The Urological Institute of NE NY, CCP, Albany

Medical & Clinical Research Associates, Bay Shore

Brooklyn Heights Urology Associates, P.C., Brooklyn

University Urology Associates, New York

Hudson Valley Urology P.C., Poughkeepsie

Northeast Urology Research, Concord

Alliance Urology Specialists, Greensboro

Urological Association of Lancaster, Lancaster

State College Urologic Association, State College

Carolina Urologic Research Center, Myrtle Beach

Lexington Urological Associates, PA, West Columbia

Urology Associates, Nashville

Lackland Air Force base, San Antonio

Urology of Virginia, Norfolk

Virginal Urology, Richmond

Virginia Urology Center, Richmond

Seattle Urology Research Center, Seattle

Roger D. Fincher, PS, Spokane

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY